[Federal Register Volume 89, Number 45 (Wednesday, March 6, 2024)]
[Notices]
[Pages 15993-15994]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-04745]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2024-0017]


Human West Nile Virus Vaccine Meeting and Request for Information

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of public teleconference and request for information.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), within 
the Department of Health and Human Services (HHS), is announcing a 
meeting and opportunity to comment on a human West Nile virus (WNV) 
vaccine. The primary purpose of the meeting is to inform critical next 
steps toward the deployment of a human WNV vaccine.

DATES: The meeting will be held on April 5, 2024, from 8 a.m. to 5 
p.m., eastern time.
    Written comments must be received on or before April 4, 2024.

ADDRESSES: You may submit written comments, identified by docket number 
CDC-2024-0017, by either of the following two methods listed below. CDC 
does not accept comments by email.
     Federal eRulemaking Portal: http://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Randall Nett, MD, MPH, Centers for Disease Control 
and Prevention, 3156 Rampart Road, MS P02, Fort Collins, CO 80521.
    Instructions: All information received in response to this notice 
must include the agency name and docket number [CDC-2024-0017]. All 
relevant comments received will be posted without change to http://www.regulations.gov, including any personal information provided. This 
will be an in-person and virtual meeting with a limited number of 
available Zoom lines. The in-person gathering will be by invitation 
only and held at Constitution Center, 400 7th St. SW, Washington, DC.
    Accessibility: For information on access or services for 
individuals with disabilities, or to request accommodations for a 
disability, please contact Shawna Zuck by email at [email protected], 
or by phone at (970) 221-6400, preferably at least 10 days before the 
meeting to allow as much time as possible to process your request.

FOR FURTHER INFORMATION CONTACT: Randall J. Nett, MD MPH, Chief, 
Arboviral Diseases Branch, 3156 Rampart Road, MS P02, Fort Collins, CO 
80521; telephone number: (970) 221-6400; email address 
[email protected].

SUPPLEMENTARY INFORMATION: 
    Background: WNV is a disease spread by mosquitoes that continues to 
cause illness and deaths each year in the United States and other areas 
of the world. Current mosquito control measures have been unsuccessful 
at decreasing the number of WNV disease cases. An approved human WNV 
vaccine could reduce the public health impact of WNV disease.
    Purpose: The primary purpose of the meeting and public comment 
period is to inform critical next steps toward the development of a 
human WNV vaccine that is approved for use.
    Attending the meeting: The meeting will be open to the general 
public. The meeting agenda and information on how to register for and 
attend the meeting online will be provided on request. If interested in 
attending the meeting online, please email [email protected]. This 
meeting is open to the public, limited only by the number of Zoom 
lines. The Zoom line will accommodate up to 500 participants and be 
available on a first come-first serve basis.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or

[[Page 15994]]

supporting materials that you consider confidential or inappropriate 
for public disclosure. If you include your name, contact information, 
or other information that identifies you in the body of your comments, 
that information will be on public display. CDC will review all 
submissions and may choose to redact or withhold submissions containing 
private or proprietary information such as Social Security numbers, 
medical information, inappropriate language, or duplicate/near-
duplicate examples of a mass-mail campaign. CDC will carefully consider 
all comments submitted into the docket.
    Oral Statements: CDC will allocate 15 minutes for the public to 
present oral comments during the meeting. Oral statements will be 
limited to three minutes per person during the public comment period. 
It is preferred that only one person present a statement on behalf of a 
group or organization. Persons interested in presenting an oral 
statement should send an email to [email protected] by 12 p.m., 
eastern time, on March 29, 2024. A limited number of time slots are 
available and will be assigned on a first come-first served basis.
    Written Public Comment: Written comments will also be accepted per 
the instructions provided in the addresses section above. Comments 
should be submitted on or before April 4, 2024.

Noah Aleshire,
Chief Regulatory Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-04745 Filed 3-5-24; 8:45 am]
BILLING CODE 4163-18-P